“The research outcome will pave a novel pathway to developing precision medicine for blood clots that can cause these devastating strokes.”
In this work with collaborator Dr Daniel Ford of The University of Sydney, Dr Liu aims to generate new knowledge in the areas of medicinal chemistry and platelet biology through the development of the PROteolysis TArgeted Chimeras (PROTACs)-based bioengineering platform.
PROTAC is a new class of chimeric molecules that represents an emerging technology for targeted therapy in drug discovery.
“PROTAC has been developed with some success for targeted cancer treatment. This grant will enable us to expand its scope and demonstrate its therapeutic potential in cardiovascular diseases like stroke, potentially saving thousands of lives,” says Dr Liu.
Related research areas
